Antibiotic biotech Dipexium files for a $35 million IPO

By Renaissance Capital,

Shutterstock photo

Dipexium Pharmaceuticals, a late stage biotech developing novel antibiotic treatments for diabetic foot ulcers, filed on Thursday with the SEC to raise up to $35 million in an initial public offering. The New York, NY-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol DPRX. Dipexium Pharmaceuticals initially filed confidentially on December 23, 2013. Oppenheimer & Co. and Feltl and Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by